NCT02958969 · OUTCOME

Frequency of Symptomatic Venous Thromboembolism

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma · Source last updated 2019-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 6 months

What was measured

Symptomatic deep vein thrombosis or pulmonary embolism

Groups in this outcome

Apixaban

apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Apixaban	50

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Apixaban	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
50
units
Participants

description

Symptomatic deep vein thrombosis or pulmonary embolism

groups

description
apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
id
OG000
title
Apixaban

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

6 months

title

Frequency of Symptomatic Venous Thromboembolism

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice